{"id":923625,"date":"2026-01-05T10:02:37","date_gmt":"2026-01-05T15:02:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/"},"modified":"2026-01-05T10:02:37","modified_gmt":"2026-01-05T15:02:37","slug":"kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/","title":{"rendered":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">EMERYVILLE, Calif., Jan.  05, 2026  (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14<sup>th<\/sup>, 2026, at 9:45 a.m. PT.<\/p>\n<p>A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.<\/p>\n<p>\n        <strong>About Kyverna Therapeutics<\/strong><br \/>\n        <br \/>Kyverna Therapeutics, Inc.\u00a0(Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna\u2019s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience.\u00a0For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u50Oeu1j74RadGYFon3nQVaoqPQvei-ZDwZgSUbm82SXQ8ni0ibzuzy2I0lO53r64DZUkdqBJCgshW_PYZGEQJilp6oMXn8Tjn6F1bNEL7Ryq5OvUQqJ5x0_zOuZV3gSTHNeMIM7xqQiRjPNVlhG6TG5XCSH30D9vhB5FMWpgfTz2GhYgmgAnN7fr7NXIoRyUojS2sS98zIqZ4tE5RgUXcO6jYSCq4O-kBYwK5ZPXQSzBxl1UjPVMkxvMClDjMiQuT9_cHtrUmL3YG6Qjsfdsef7xmdn8jYBwJPc6csmt-A83vXLUKhCIB3neaS5L6uemmohtKy0KQUT24vH8KKL1lC7D3wXpfMqeXOs0DLj7wPMOEcmFTfqexBuy-nGHBYjEH8PhPU0yPi9rRHQFtaCSqBUdZ9Yg_oAT0zDoKp9QjpiqNLy1Q5i3uCwISR_t6MbluNsyA3vHvA1BmvrN7TxTbbhR2wiVzoAnu9JRuT4nqAKKI0HuiqMNRbo9FB51oZeS8JEbCRMe1MaElPNfjbfaGShKQe--g3szPyY1KK9i7E9KQgyl2Ac0NE-bMbnlsQa99vrehMTz_LVYM-V8qxJJZUHIiEi385cHzCAqRJ6mZ3HwiQkxP9od71L_Ehs8YOskzp-HzieX4Iv2-ho6QfYo33FCl0XU3jKsS71wDXWgty3FRTar8gGx3vhhfUKswcV42XQ8xToiXGp6SX2zrlufQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/kyvernatx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\u00a0<br \/>Investors:\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J3xUcL1epEmgW3PPMRun6VSECBtTU_YmCCPrdeLfZKaEVE9W44qSKR_-q8XaVDY4be9AjiqSbsmmmsv4-eQNhJNFkdAcrjLEIMmQKPOSnZ8_PRY9qLEVO0khTn2xn6JfIzrCO4_70DlH419bhLWYI9XVrhrJlED9cOiDqUP9NoZ1EGRTipAOlygc1QkHgyq2h1AU1YxvedEvXug6hkTTXpHVv9mXi1AvWy0lXVWz1i2CTqVMCohyn3D1iJBxLLRfaltIw_e8nu6XxO8XpGvGTxYdTcTgjZJwX2qPr0hKnJgyZss0GDlZ7f7JpCmntqZwHUJymHs1icqoojP7wYWV_1TOg0ZZvsu4OFiG3sa3FXtZc9xiHKlvElXjrphlaUNKv0Mj3vPJRR4EAKHluKUlEibcmS3pZke3g6GrvTQxlwAT0fuZl6FpdearpvrHQottnN8TSuzlTuf7Zs7G03QqXbW1q2BZ-H7VOOntD_ar6S-lhCBpzXwhnA2GKftAboUi9rKT7ffxhCKLTE-7mavM9fdW3Kzos8Fp3EXI2OCaBMwpTE__z0oZxptegRJGMtrxfTJltMvdObeeVA1b4dC_RQ==\" rel=\"nofollow\" target=\"_blank\">InvestorRelations@kyvernatx.com<\/a><br \/>Media:\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SrX_AQYzysDnnMx3ZWPVa0k8zPbFdsTNbNfQsBK65E6Yn2Mfbeu9voUP3WRVuvV-zK2qtbC040NdqC8VTZHOWuNSBi3MVLAdl00eIt2-M5Nz_jmi6Ky-adbghvZ5k6aHPcKaUycrAMx0cI71VIFJF_6TkCOYnZ-_IZhxeee679pv4denJ8HwZ_McOzQDESSnjaDmzaVKll4HUpa7klNZNd3O2MY_qwrPf9r_-pLv_QvQ8B4TAvfSfgqUfVA5OtswxnFHoQV0VKHDc4-IPWrhsHPQ6WoiswJ8-gr3xiCHhW7B1QVJ6w67CYnrZZuWTQwCw2NAz6gtM3Kj2_BzGKmthgRLuZwDrMdmd8x5_sdOlbGNOITqYaYgB3Ik9jzKo1WRFZy_iY9x88-dJ9Tbsqok8IT4D4fVqpRmNFTkP95O3uAldFfNkLKWruh--CJezKOwxg6Uf4aUjx0sMHW4UarY4p7gs25akoPoCwv7Zc1lArOLm4kjXkAweb0pwS8ILicW\" rel=\"nofollow\" target=\"_blank\">media@kyvernatx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDM0NGE5NjYtMzQxNy00MzE3LWFmYTQtMWFjOWUyN2FiNDhmLTEyNzQzMjItMjAyNi0wMS0wNS1lbg==\/tiny\/Kyverna-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna Therapeutics Kyverna Therapeutics, Inc.\u00a0(Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-923625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna Therapeutics Kyverna Therapeutics, Inc.\u00a0(Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. &hellip; Continue reading &quot;Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T15:02:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference\",\"datePublished\":\"2026-01-05T15:02:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/\"},\"wordCount\":245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/\",\"name\":\"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\",\"datePublished\":\"2026-01-05T15:02:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk","og_description":"EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna Therapeutics Kyverna Therapeutics, Inc.\u00a0(Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. &hellip; Continue reading \"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-05T15:02:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference","datePublished":"2026-01-05T15:02:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/"},"wordCount":245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/","name":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=","datePublished":"2026-01-05T15:02:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODMzMSM3MzQwMDU3IzIyNjI3NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-to-present-at-the-j-p-morgan-2026-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=923625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=923625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=923625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=923625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}